Keytruda plus chemotherapy is now a first-line treatment for pleural mesothelioma, replacing chemotherapy alone as the standard of care. The KEYNOTE-483 trial showed significant improvements in ...

RAHWAY, N.J.& KINGSTON, Ontario---- Merck, known as MSD outside of the United States and Canada, and the Canadian Cancer Trials Group today announced that the Phase 2/ 3 CCTG IND.227/KEYNOTE-483 ...

Keytruda plus chemo has been approved for unresectable advanced or metastatic malignant pleural mesothelioma based on findings from the KEYNOTE-483 trial. The Food and Drug Administration (FDA) ...

The FDA has approved Keytruda in combination with pemetrexed and platinum chemotherapy, as first-line Tx of unresectable advanced or metastatic malignant pleural mesothelioma.

Pleural mesothelioma is a type of cancer that develops in the tissue that lines the lungs or pleura. The European Commission will now review the CHMP’s opinion and a final decision from the ...

Malignant Pleural Mesothelioma KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or ...

(RTTNews) - Drug major Merck & Co., Inc. (MRK) announced Wednesday that the U.S. Food and Drug Administration has approved its anti-PD-1 therapy KEYTRUDA (pembrolizumab), in combination with ...

Keytruda is approved for a range of indications globally and drummed up more than $25 billion in sales in 2023. In the company's most recent quarter, Keytruda sales rose 16% to $7.3 billion.

Merck & Co. has won its first U.S. approval for use of its blockbuster cancer drug Keytruda in patients with malignant pleural mesothelioma, a rare cancer that grows in the membrane that lines the ...

Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated ...